Acrux Limited ASX: ACR Share Price & Review

ACR Overview

ACR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About ACR

Website

Acrux Limited

Telephone

61.3.8379.0100

Address

103-113 Stanley Street West Melbourne, Victoria (VIC) 3003

Description

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. Its products brands include AXIRON, ELLAVIE & EVAMIST and RECUVYRA. The company was founded by Ross Dobinson and Barrie Charles Finnin in 1998 and is headquartered in West Melbourne, Australia.

ACR Price Chart

Key Stats

Market Cap

AU$12.79M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.1

Trade Value (12mth)

AU$6,260.00

1 week

2.27%

1 month

-16.67%

YTD

-8.16%

1 year

7.14%

All time high

4.52

Key Fundamentals

EPS 3 yr Growth

-65.20%

EBITDA Margin

-158.40%

Operating Cashflow

-$4m

Free Cash Flow Return

-53.60%

ROIC

-72.20%

Interest Coverage

N/A

Quick Ratio

1.60

Other Data

Shares on Issue (Fully Dilluted)

290m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACR Announcements

Latest Announcements

Date	Announcements
21 November 24	AGM Presentation × AGM Presentation
31 October 24	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
15 October 24	Notice of Annual General Meeting/Proxy Form × Notice of Annual General Meeting/Proxy Form
02 October 24	FY24 R&D Tax Incentive rebate received × FY24 R&D Tax Incentive rebate received
24 September 24	ASX Small and Mid Cap Conference presentation × ASX Small and Mid Cap Conference presentation
29 August 24	Appendix 4E and FY24 Full Year Statutory Accounts × Appendix 4E and FY24 Full Year Statutory Accounts
29 August 24	Appendix 4G and Corporate Governance Statement FY24 × Appendix 4G and Corporate Governance Statement FY24
29 August 24	FY24 Full Year Results - Investor Presentation × FY24 Full Year Results - Investor Presentation
29 August 24	Investor Webinar Information - FY24 Results × Investor Webinar Information - FY24 Results
27 August 24	FDA Approval received for Dapsone Gel, 7.5% × FDA Approval received for Dapsone Gel, 7.5%
26 July 24	Quarterly Activities Report and Appendix 4C - June 2024 × Quarterly Activities Report and Appendix 4C - June 2024
15 July 24	Acrux presentation to Bioshares, 18th Biotech Summit × Acrux presentation to Bioshares, 18th Biotech Summit
28 June 24	RDTI funding facility secured × RDTI funding facility secured
13 June 24	Acrux presentation at Hidden Gems in Lifesciences Forum × Acrux presentation at Hidden Gems in Lifesciences Forum
30 April 24	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
30 April 24	Quarterly Activities and Appendix 4C, reissued × Quarterly Activities and Appendix 4C, reissued
03 April 24	Launch of Dapsone 5%, Gel in the United States × Launch of Dapsone 5%, Gel in the United States
05 March 24	Application for quotation of securities - ACR × Application for quotation of securities - ACR
05 March 24	Appendix 3Y Brumley × Appendix 3Y Brumley
05 March 24	Appendix 3Y Dobinson × Appendix 3Y Dobinson
27 February 24	Appendix 4D and Half Year Accounts × Appendix 4D and Half Year Accounts
27 February 24	Investor Presentation Half Year Accounts × Investor Presentation Half Year Accounts
23 February 24	Investor Webinar Details - Financial Results 1H FY24 × Investor Webinar Details - Financial Results 1H FY24
14 February 24	Notification regarding unquoted securities - ACR × Notification regarding unquoted securities - ACR
14 February 24	Application for quotation of securities - ACR × Application for quotation of securities - ACR

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACR Shortsell

Frequently Asked Questions

What is the current share price of Acrux Limited (ACR:ASX)?

The current share price of Acrux Limited (ACR:ASX) is AU$0.046.

What is the 52-week high share price for Acrux Limited (ACR:ASX)?

The 52-week high share price for Acrux Limited (ACR:ASX) is AU$0.10.

What is the 52-week low share price for Acrux Limited (ACR:ASX)?

The 52-week low share price for Acrux Limited (ACR:ASX)? is AU$0.04.

What is the dividend yield for Acrux Limited (ACR:ASX)?

Acrux Limited (ACR:ASX) does not pay a dividend.

What was Acrux Limited (ACR:ASX) last dividend payment?

The last dividend payment of Acrux Limited (ACR:ASX) is AU$0.06.

What is the franking level for Acrux Limited (ACR:ASX)?

Acrux Limited (ACR:ASX) has a franking level of 0.0%.

In which sector is Acrux Limited (ACR:ASX) classified?

Acrux Limited (ACR:ASX) is classified in the Healthcare.

The current P/E ratio for Acrux Limited (ACR:ASX) is .

Company

Important

Get the latest insights and hot tips delivered right to your inbox

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

ACR · ASX

Acrux Limited (ASX:ACR)

AU$0.046

ACR Overview

ACR Health Scores

About ACR

ACR Price Chart

Key Stats

AU$12.79M

N/A

N/A

Dividends Overview

N/A

N/A

N/A

Market Data

Key Fundamentals

Other Data

ACR Announcements

Latest Announcements

AGM Presentation

Quarterly Activities/Appendix 4C Cash Flow Report

Notice of Annual General Meeting/Proxy Form

FY24 R&D Tax Incentive rebate received

ASX Small and Mid Cap Conference presentation

Appendix 4E and FY24 Full Year Statutory Accounts

Appendix 4G and Corporate Governance Statement FY24

FY24 Full Year Results - Investor Presentation

Investor Webinar Information - FY24 Results

FDA Approval received for Dapsone Gel, 7.5%

Quarterly Activities Report and Appendix 4C - June 2024

Acrux presentation to Bioshares, 18th Biotech Summit

RDTI funding facility secured

Acrux presentation at Hidden Gems in Lifesciences Forum

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities and Appendix 4C, reissued

Launch of Dapsone 5%, Gel in the United States

Application for quotation of securities - ACR

Appendix 3Y Brumley

Appendix 3Y Dobinson

Appendix 4D and Half Year Accounts

Investor Presentation Half Year Accounts

Investor Webinar Details - Financial Results 1H FY24

Notification regarding unquoted securities - ACR

Application for quotation of securities - ACR

Dividends

Key Stats

N/A

N/A

N/A

N/A

Values and Recommendations

Key Stats

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

0.00%

0

N/A

N/A

N/A

N/A

Discover Short-sellingOpportunities

ACR Shortsell

Related Companies

Frequently Asked Questions

Company

Company

Important

Discover
Short-selling
Opportunities